GlassScriptPhysician profile
Kenneth A Knowles
NPI 1811958564
$8,499.25
in general payments reported to CMS, 2019-2025
29 companies · $996 in 2025
The $996 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,352 · 2020: $996 · 2021: $1,247 · 2022: $1,627 · 2023: $1,244 · 2024: $1,036 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,277.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,570.71 | 2019-2025 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $1,349.76 | 2019-2025 | Veltassa |
| Amgen INC. | $630.23 | 2019-2024 | Tavneos, Parsabiv, Aranesp |
| Bayer Healthcare Pharmaceuticals INC. | $487.27 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $471.08 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $390.60 | 2021-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $375.71 | 2019-2025 | Velphoro |
| Otsuka America Pharmaceutical, INC. | $343.14 | 2019-2025 | Jynarque |
| Alexion Pharmaceuticals, INC. | $293.75 | 2019-2024 | Ultomiris |
| Travere Therapeutics, INC. | $276.82 | 2023-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $261.83 | 2020-2025 | Acthar |
| Glaxosmithkline, LLC. | $256.41 | 2023 | Jesduvroq, Benlysta |
| Akebia Therapeutics INC | $235.64 | 2019-2025 | Vafseo, Auryxia |
| Novo Nordisk INC | $206.53 | 2023-2025 | Ozempic, Rybelsus |
| Ani Pharmaceuticals, INC. | $203.46 | 2023-2025 | Purified Cortrophin Gel |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $177.88 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $146.97 | 2022-2024 | |
| Opko Pharmaceuticals, LLC | $143.14 | 2019-2024 | Rayaldee |
| Abbvie INC. | $125.00 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $101.75 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.68 | 2023-2025 | Jardiance |
| Mallinckrodt Enterprises LLC | $94.39 | 2019 | |
| Edwards Lifesciences Corporation | $69.23 | 2019 | |
| Daiichi Sankyo INC. | $46.73 | 2019-2020 | |
| Ardelyx, INC. | $45.06 | 2023-2024 | Ibsrela |
| Ultragenyx Pharmaceutical INC. | $42.10 | 2024 | Crysvita |
| Shire North American Group INC | $21.84 | 2019 | |
| Horizon Therapeutics Plc | $19.06 | 2022 | |
| Csl Behring | $16.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Knowles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.